Sales of Ozempika analogues increased 3-fold in 2025

Sales of semaglutide-based Ozempika analogues, which are produced by Russian Geropharm, Promomed, PSK Pharma, and Iran's Cinnagen, increased 3-fold by the end of 2025 and amounted to ₽29.2 billion. In kind, sales increased 3.2 times. In 2025, another substance appeared on the Russian market of anti—obesity drugs - tirzepatide, a drug based on which Promomed produces. Sales of drugs based on tirzepatide at the end of the year amounted to ₽8.9 billion, or 918,000 packages.